Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$11.33 USD
0.00 (0.00%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $11.33 0.00 (0.00%) 7:26 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Pliant Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -161.34 | -123.32 | -97.26 | -41.53 | -0.63 |
Depreciation/Amortization & Depletion | -3.15 | 0.02 | 1.54 | 1.31 | 1.11 |
Net Change from Assets/Liabilities | 1.25 | 4.22 | 6.92 | -1.21 | -5.06 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 46.87 | 24.46 | 13.37 | 4.16 | 1.83 |
Net Cash From Operating Activities | -116.36 | -94.63 | -75.44 | -37.27 | -2.75 |
Property & Equipment | -0.92 | -1.76 | -1.95 | -1.53 | -0.96 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -126.09 | -148.44 | 75.65 | -209.33 | -16.97 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -127.01 | -150.20 | 73.70 | -210.87 | -17.93 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 275.25 | 227.41 | 2.98 | 213.21 | 48.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.85 | -0.56 | -0.46 | 0.00 | -2.58 |
Net Cash from Financing Activities | 274.41 | 226.85 | 2.53 | 213.21 | 45.54 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 31.03 | -17.98 | 0.78 | -34.93 | 24.86 |
Cash at Beginning of Period | 33.68 | 51.67 | 50.88 | 85.81 | 60.95 |
Cash at End of Period | 64.72 | 33.68 | 51.67 | 50.88 | 85.81 |
Diluted Net EPS | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 |
Fiscal Year End for Pliant Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -102.81 | -46.96 | -161.34 | -120.23 | -78.74 |
Depreciation/Amortization & Depletion | 2.08 | 1.60 | -3.15 | -8.84 | -5.58 |
Net Change from Assets/Liabilities | 3.02 | 4.73 | 1.25 | 0.64 | 3.08 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 22.14 | 10.35 | 46.87 | 37.16 | 26.21 |
Net Cash From Operating Activities | -75.57 | -30.27 | -116.36 | -91.26 | -55.04 |
Property & Equipment | -2.74 | -1.49 | -0.92 | -0.86 | -0.77 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 72.99 | 61.04 | -126.09 | -158.07 | -196.42 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 70.25 | 59.55 | -127.01 | -158.93 | -197.19 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.56 | 1.88 | 275.25 | 275.02 | 274.25 |
Issuance (Repayment) of Debt | 19.91 | 19.91 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.85 | -0.83 | -0.76 |
Net Cash from Financing Activities | 22.47 | 21.79 | 274.41 | 274.19 | 273.49 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 17.15 | 51.06 | 31.03 | 23.99 | 21.27 |
Cash at Beginning of Period | 64.72 | 64.72 | 33.68 | 33.69 | 33.69 |
Cash at End of Period | 81.87 | 115.78 | 64.72 | 57.68 | 54.95 |
Diluted Net EPS | -0.92 | -0.78 | -0.68 | -0.70 | -0.70 |